Portal de investigación
Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Brunner HI
- Ruperto N
- Zuber Z
- Cuttica R
- Keltsev V
- Xavier RM
- Burgos-Vargas R
- Silverman ED
- Espada G
- Ferrandiz Zavaler M
- Kimura Y
- Duarte C
- Job-Deslandre C
- Joos R
- Douglass W
- Wimalasundera S
- Bharucha KN
- Wells C
- Lovell DJ
- Martini A
- De Benedetti F
- Paediatric Rheumatology International Trials Organisation (PRINTO), the Pediatri
Grupos
Abstract
Report the 2-year efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA).
Datos de la publicación
- ISSN/ISSNe:
- 2326-5191, 2326-5205
- Tipo:
- Article
- Páginas:
- 530-541
- DOI:
- 10.1002/art.41528
- PubMed:
- 32951358
- Factor de Impacto:
- 4,106 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
Arthritis & Rheumatology WILEY
Citas Recibidas en Web of Science: 40
Documentos
- No hay documentos
Filiaciones
Keywords
- Biologicals, clinical trial, juvenile idiopathic arthritis, pediatric rheumatology
Campos de Estudio
Cita
Brunner HI,Ruperto N,Zuber Z,Cuttica R,Keltsev V,Xavier RM,Burgos R,CALVO I,Silverman ED,Espada G,Ferrandiz M,Kimura Y,Duarte C,Job C,Joos R,Douglass W,Wimalasundera S,Bharucha KN,Wells C,Lovell DJ,Martini A,De Benedetti F,Paediatric Rheumatology International Trials Organisation (PRINTO) TP. Efficacy and Safety of Tocilizumab for Polyarticular-Course Juvenile Idiopathic Arthritis in the Open-Label 2-Year Extension of a Phase 3 Trial. Arthritis Rheumatol. 2020. 73. (3):p. 530-541. IF:10,995. (1).